Adult malignant mesenchymoma
disease diseaseOn this page
Also known as malignant mesenchymomamalignant mesenchymoma of adults
Summary
Adult malignant mesenchymoma (MONDO:0003692) is a disease and 6 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, dactinomycin, and filgrastim. A subtype of malignant mesenchymoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult malignant mesenchymoma |
| Mondo ID | MONDO:0003692 |
| DOID | DOID:5894 |
| NCIT | C7947 |
| UMLS | C0279548 |
| MedGen | 83523 |
| Is cancer (heuristic) | no |
Also known as: adult malignant mesenchymoma · malignant mesenchymoma · malignant mesenchymoma of adults
Disease family
This is a subtype of malignant mesenchymoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mesenchymoma › adult malignant mesenchymoma
Related subtypes (1): childhood malignant mesenchymoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00003958 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma |
| NCT00346164 | PHASE3 | COMPLETED | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma |
| NCT00112463 | PHASE2 | COMPLETED | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma |
| NCT01154452 | PHASE1/PHASE2 | COMPLETED | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma |
| NCT00720174 | PHASE1 | COMPLETED | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma |
| NCT04758325 | Not specified | RECRUITING | The Sarcoma Biology and Outcome Project |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CYCLOPHOSPHAMIDE ANHYDROUS | 4 | 1 |
| DACTINOMYCIN | 4 | 1 |
| FILGRASTIM | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SARGRAMOSTIM | 4 | 1 |
| TOPOTECAN HYDROCHLORIDE | 4 | 1 |
| VINCRISTINE SULFATE | 4 | 1 |
| VISMODEGIB | 4 | 1 |
| CIXUTUMUMAB | 2 | 1 |
| CHEMBL4748391 | 0 | 1 |
| CHEMBL4066465 | 0 | 1 |